CACLP - The largest IVD Expo & Conference

Abcam Acquires Knockout Cell Lines, Lysates Portfolio From E

Industry news | 31 July, 2019 | CACLP


Life science reagents and tools company Abcam announced today that it has acquired genome editing technologies firm EdiGene's live cell line and lysates portfolio.
 
Financial terms of the deal were not disclosed.
 
EdiGene has developed an off-the shelf diploid library of more than 2,800 single clonal knockout cell lines, targeting more than 2,600 genes in commonly used human cancer cell lines — including HeLa, HEK293-T, A549, HCT116, Hep G2 and MCF7, Abcam said. Ready-made diploid knockout cell lines can be used for antibody validation, in the study of biological pathways and disease models, and for screening and cellular assays.
 
"We are excited to be able to bring the same level of industry-leading quality and data to the cell lines market as we have to research antibodies," Cheri Walker, Abcam's senior vice president of corporate development, said in a statement. "The cell line market is in the early stages of development as a research tool, where the provision of more choice, with the right gene targets in the right cell lines, will allow the market to rapidly expand."
 
EdiGene CEO Dong Wei added that the sale of the portfolio to Abcam comes on the heels of the firm's strategic decision to focus on its pipeline of biotherapeutic products and high-throughput genome screening services. The company raised $10 million in a Series pre-B Plus financing round in February, which it said validated its strategy of translating its proprietary platforms into potential therapeutics.
 
The lysate products will be available on Abcam's website early in the fourth quarter, the company noted. The expanded cell line offerings will follow throughout 2020.
 
Abcam also said it will use these products to support further knockout antibody validation as a part of its ongoing antibody quality initiative. In April, the company signed a deal to provide NanoString Technologies with custom panels for its GeoMx Digital Spatial Profiler platform from Abcam's collection of 6,000-plus recombinant monoclonal antibodies, which have been validated for use in fresh frozen and formalin-fixed paraffin-embedded tissue.
Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference